Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal-Making Perspectives: GSK/Pfizer HIV Venture Offers Transformational Strategy

Executive Summary

Real innovation in deal-making, like pharma R&D, is a rare commodity. As with R&D, deal-making innovation often gets blocked by entrenched interests or misunderstanding or simple inertia. There are lots of reasons not to repeat the single most innovative and successful transaction of all time - Genentech/Roche - but none of them outweigh the spectacular opportunity that deal created
Advertisement

Related Content

Ernst & Young: “Optionality” Here To Stay, As Biotech Business Model Reinvents Itself
Glaxo and Pfizer Form An HIV Company; Spin-Off Next?
The GSK/Pfizer HIV Venture: Another Sign of Change?
The GSK/Pfizer HIV Venture: Another Sign of Change?
GSK Tries to Mimic Real-World Biotech
GSK Tries to Mimic Real-World Biotech

Topics

Advertisement
UsernamePublicRestriction

Register

PS051087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel